Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, discusses three important studies focusing on newer therapies for patients with recurrent platinum-sensitive, platinum-agnostic, and advanced recurrent ovarian cancers (Abstracts 6003, 6004, and 6005).
Roy S. Herbst, MD, PhD, of Yale Cancer Center, discusses data from the ADAURA study, which showed that compared with placebo, osimertinib as adjuvant therapy after complete t...
Nirav Niranjan Shah, MD, of the Medical College of Wisconsin, explores whether autologous transplantation, in patients with relapsed diffuse large B-cell lymphoma who achieve...
Christopher Nutting, MD, PhD, of the Royal Marsden Hospital and Institute of Cancer Research, discusses phase III results from the first study to demonstrate the functional b...
Farhad Ravandi-Kashani, MD, of The University of Texas MD Anderson Cancer Center, discusses updates from a phase I dose-escalation study of AMG 330, a bispecific T-cell engag...
Howard A. Burris III, MD, FACP, FASCO, talks about some of the reports of research developments he is looking forward to and how future conferences could incorporate virtual ...